Endpoint Clinical Unveils Elosity R3 to Tackle Trial Complexity with AI

RALEIGH, NC – April 13, 2026 – Endpoint Clinical today announced a significant upgrade to its clinical trial management technology, releasing Elosity® R3, a new version of its Randomization and Trial Supply Management (RTSM) platform. The update is engineered to address the escalating complexities of modern pharmaceutical research by integrating advanced supply chain capabilities with a sophisticated, conversational Artificial Intelligence engine, aiming to provide trial sponsors and contract research organizations (CROs) with unprecedented operational clarity and control.

The release comes as the clinical trial landscape grows increasingly challenging. Studies are more frequently global, involve adaptive designs that change based on interim results, and incorporate decentralized elements that add logistical hurdles. Elosity R3 is designed to meet these challenges head-on, enhancing how clinical teams plan, execute, and monitor every phase of a trial.

Taming the Labyrinth of the Modern Supply Chain

A core focus of the Elosity R3 release is the fortification of clinical supply chain management. Modern trials, particularly large-scale Phase III studies that dominate the market, often span dozens of countries and hundreds of sites, creating a logistical labyrinth where a single delay can have cascading effects. Endpoint, which has supported over 2,000 studies across more than 90 countries, has built new features directly targeting these pain points.

The R3 update introduces central pharmacy management, a critical feature for studies requiring specialized drug preparation or handling at a regional hub before distribution to clinical sites. This capability provides a new layer of control and visibility, which is essential for complex therapies. Furthermore, the platform now supports more flexible sourcing strategies and enhanced portfolio-level supply optimization, allowing sponsors to manage and pool investigational products more efficiently across multiple ongoing trials, reducing waste and mitigating the risk of stockouts.

Another significant enhancement is the formal support for patient rollover, which simplifies the process of transitioning patients from one study to another, such as moving from a primary treatment trial to a long-term extension study. This has historically been a manual and error-prone process, and its integration into the RTSM platform streamlines data continuity and supply logistics for long-term patient engagement.

These features are not just incremental improvements; they represent a direct response to an industry grappling with the operational weight of its own innovation. As trials for oncology, rare diseases, and personalized medicine become the norm, the demand for RTSM systems that can handle dynamic, multi-layered supply logic has become acute.

The Dawn of Conversational AI in Trial Management

Perhaps the most forward-looking aspect of the Elosity R3 release is the major expansion of its built-in AI, eloAI. While other major RTSM providers like Oracle and Signant Health have integrated AI-powered predictive forecasting, Endpoint is pushing the boundary by enabling clinical teams to interact with complex trial data using natural language.

This conversational AI allows authorized users to ask direct questions—such as "What is the current enrollment rate in Germany?" or "Visualize the inventory levels for Lot XYZ across all depots"—and receive real-time answers, visualizations, and analytics directly within the platform. This capability promises to democratize data access, moving it beyond the realm of data scientists and programmers and putting powerful insights directly into the hands of clinical operations managers and supply planners.

According to the company, the system is designed to accelerate the cycle from question to answer, enabling teams to identify and resolve potential issues faster than ever before. Critically, Endpoint emphasizes that eloAI operates within the strict regulatory framework of clinical trials. The system is built to preserve study blinding, enforce role-based access controls, and maintain a full audit trail, ensuring that the use of powerful AI does not compromise trial integrity or compliance with FDA and EMA guidelines.

This user-centric approach to AI differentiates Elosity in a market where AI is often a back-end engine for optimization. By creating a conversational interface, Endpoint is betting that improving the human-computer interaction is as important as improving the underlying algorithms.

A Strategic Move in a Competitive Market

The launch of Elosity R3 is a calculated strategic move by Endpoint Clinical in the highly competitive RTSM market. The company competes with established giants like Medidata (a Dassault Systèmes company), Oracle Health Sciences, and the rapidly growing Veeva Systems. In this environment, differentiation is key, and Endpoint is positioning itself as a focused, best-in-class RTSM specialist.

This release reinforces the company's strong market position, which was validated when it was named a Leader in the 2025 Everest Group Life Sciences RTSM Products PEAK Matrix® Assessment. The update aligns perfectly with major industry trends, including the shift toward unified, cloud-based platforms and the increasing demand for embedded intelligence. Elosity’s "integration-first" architecture ensures it can serve as a central hub, connecting with various other eClinical systems like Electronic Data Capture (EDC) and Clinical Trial Management Systems (CTMS) to provide a single source of truth.

"Elosity R3 represents a meaningful step forward in how RTSM platforms support modern clinical trials," said Jeff Rubesin, Vice President of Product Strategy at Endpoint Clinical, in the company's official announcement. "We built Elosity to connect trial execution, clinical supply operations, and data insight within a single platform. With R3, sponsors and CROs gain faster operational visibility, stronger governance, and the flexibility to adapt as trials evolve."

By delivering a platform that is both powerful in its logistical capabilities and intuitive in its use of AI, Endpoint Clinical is aiming to solidify its role as a critical technology partner for organizations navigating the future of drug development. The Elosity R3 platform is available immediately to sponsors and CROs worldwide, offering a new suite of tools to help control the controllables in the unpredictable world of clinical research.